PUBLISHER: Grand View Research | PRODUCT CODE: 1985904
PUBLISHER: Grand View Research | PRODUCT CODE: 1985904
The global companion animal health market size was estimated at USD 25.46 billion in 2025 and is projected to reach USD 56.41 billion by 2033, growing at a CAGR of 10.6% from 2026 to 2033. The market is primarily driven by factors such as rapid advancements in the field of companion animal health, increase in zoonotic disease transfer from pets, evolving regulations, and rising R&D & procedural advancements.
Rapid innovation across therapeutics, diagnostics, and care delivery is transforming the companion animal health industry to resemble human healthcare in both complexity and value. Some of the advances in molecular biology, biologics, and formulation science enable targeted therapies that address specific disease pathways and support long-term disease management. Some of the regulatory actions, reflect growing acceptance of precision-driven veterinary medicines. For instance, the FDA, in April 2025, expanded treatment availability other than traditional pets by adding Faunamor to its Index of Legally Marketed Unapproved New Animal Drugs for Minor Species. Similarly, adoption of AI in diagnostics, regenerative medicine, and advanced referral infrastructure is improving clinical outcomes and operational efficiency.
The market is also driven by rising awareness of zoonotic diseases transmitted from pets to humans. As pets share indoor living spaces with families, risks associated with parasites, bacterial infections, and vector-borne diseases have moved into everyday public health conversations. Public health agencies such as the U.S. Centers for Disease Control and Prevention in their May 2025 publication highlighted that common pet-associated illnesses range from salmonellosis and ringworm to vector-borne infections transmitted through fleas and ticks, strengthening the need for preventive veterinary intervention at scale (CDC). This shift has incorporated preventive veterinary care such as routine vaccinations, parasite control, and regular screenings into standard pet ownership practices. Besides this, veterinarians emphasize year-round prevention and integrated wellness plans, driving recurring demand for pharmaceuticals, diagnostics, and vaccines.
Furthermore, evolving regulatory frameworks are playing a pivotal role in accelerating the growth of companion animal health industry by improving product approval efficiency, strengthening international cooperation, and modernizing outdated laws that historically slowed innovation. For instance, December 2025 updates from the U.S. FDA's Center for Veterinary Medicine (CVM) show a steady stream of approvals for new animal drugs, such as treatments for congestive heart failure and novel antiseptic formulations, which reflects regulators' willingness to evaluate and authorize important companion animal therapies in a timely manner. Similarly, industry groups adopt modernized regulatory pathways that reflect scientific complexity and innovation pace. A veterinary industry panel convened by the American Veterinary Medical Association in July 2025, highlighted the need for modernization of regulatory processes governing animal health products and nutrition, calling for enhancements in drug review efficiency and more agile frameworks that reflect the complexity of current innovations.
Global Companion Animal Health Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global companion animal health market report based on animal, product, distribution channel, end use and region: